Predictive Diagnostics Market Size Share Value Analysis 2023-2030

Predictive Diagnostics Market size was valued at USD 1284.85 million in 2022 and is expected to reach USD 2751.02 million by 2030, growing at a CAGR of 10.3% during the forecast period (2023-2030). Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, Predictive diagnostics can assist deliver impactful and measurable advancements to operations.

Implantable Cardiac Pacemaker Treatment Market Report Scope

Metrics	Details
Market CAGR	10.3%
Segments Covered	By Application, By Type, By End Users, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

To Get a Free Sample Click here

Market Dynamics

The global predictive diagnostics market is driven by technological advancements, growing adoption of predictive diagnostics in research and development, rising lifestyle disease, and an increasingly health-conscious population.

Increasing benefits of predictive diagnostics in healthcare drives market growth

The technological advancements in diagnostics sectors drive the market in the forecast period. According to the Philips report, June 2020, predictive analytics in healthcare help detect early signs of patient degeneration in intensive care units and general wards, recognize at-risk patients in their residences to prevent hospital readmissions, and prevent avoidable downtime of medical equipment. Predictive diagnostics allows combining data from multiple sources – including hospital-based electronic medical records, fall detection pendants, and the historical use of medical alert services – to identify seniors at risk of emergency transport in the next 30 days. Predictive diagnostics allows healthcare providers to reach out to a senior person before a fall or another medical complication occurs, preventing unnecessary hospital readmissions and reducing transportation, acute care, and rehabilitation costs.

In addition, the market players are applying the market strategies such as product launches and collaboration to expand their business. For instance, in October 2021, bioMérieux - a French multinational biotechnology firm focusing on in-vitro diagnostics - launched predictive Diagnostics, the company’s new offering in food safety and food quality. Also, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease. In this agreement, QIAGEN will design and validate a clinical trial assay that will detect a mixture of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease to an LRRK2 inhibitor. Furthermore, this partnership will support the clinical development of Neuron23’s drug candidate, which is presently in the late stages of preclinical development. Subject to further clinical development, the agreement also enfolds options for developing additional companion diagnostics.

The lack of expertise in predictive diagnostics testing will hamper the growth of the market

However, less reliability of biomarkers for identifying chronic degenerative diseases and lack of expertise in predictive diagnostics testing will restrain the market in the forecast period.

COVID-19 Impact Analysis

The appearance of COVID-19 positively impacted the global predictive diagnostics market. As per the article published in Advances in Biomarker Sciences and Technology in 2020, biomarkers are particularly important during a pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Biomarkers can be applied to describe observable characteristics of certain diseases and determine optimal treatments based on these phenotypes and genotypes; thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide). These biomarkers play a pivotal role in predicting future complications or disease severity and could be useful as an indicator for COVID-19 prognosis.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period 2023-2030

By Type:

Presymptomatic
Predispositional

By Application:

Cardiovascular Diseases
Neurological Diseases
Genetic Diseases
Oncology
Others

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most familiar cancers are breast, colon, lung, rectum, and prostate. Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

As per the article published in Frontiers in Oncology in September 2022, predictive biomarkers in the context of progressive disease treated with chemotherapy are also included. A meta-analysis of clinicopathological features that predict necrosis/fibrosis in retroperitoneal residual masses of non-seminoma patients, including histopathological features in the orchiectomy specimen (absence of teratoma, presence of seminoma), as well as serum tumor markers (normal HCG and AFP, elevated LDH) and size of the mass (>50% change in size, smaller residual mass size). A

Also, identified features that predict the development of choriocarcinoma syndrome (a severe complication, challenging to treat and with considerable mortality) in poor-risk germ cell tumor patients, including metastatic lung involvement of more than half and ECOG PS around two. Rising cancer cases and demand for predictive diagnostics drives the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global predictive diagnostics market

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. The market is driven by improved healthcare infrastructure, the increasing incidence of infectious disease, active regional key players, and easy availability of products in the region.

The market players are offering predictive diagnostics in the North American region. For instance, F. Hoffmann-La Roche Ltd provides predictive diagnostics solutions for oncology, cardiovascular disease, infectious disease, respiratory disease, autoimmune disease and more.

In addition, key players are adopting the market strategies such as acquisition and product launches. For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases.

Competitive Landscape

The predictive diagnostics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc, Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the predictive diagnostics market globally.

For instance,

In September 2021, Janssen-a pharmaceutical subsidiary of Johnson & Johnson - introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatments and therapies.

QIAGEN

Overview:

QIAGEN is a German organization founded in 1984 and headquartered in Hilden, Germany. It delivers the solutions for molecular testing and provides the answer from the building blocks of life- DNA, RNA, and protein to the customers to unblock the new insights.

Product Portfolio:

NextSeq 550Dx: This instrument is FDA-regulated and CE-in vitro diagnostic (IVD) marked, allowing clinical laboratories to design and execute a broad range of applications, from Next Generations sequencing solutions IVD assays using targeted panels to clinical research applications that include techniques from targeted panels to whole genomes.

The global predictive diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages

Predictive Diagnostics Market